期刊文献+

不同配比的哌拉西林/他唑巴坦治疗医院获得性肺炎疗效观察 被引量:5

Effect of different proportions of piperacillin/tazobactam on treatment of hospital acquired pneumonia
原文传递
导出
摘要 目的探讨不同配比的哌拉西林/他唑巴坦治疗医院获得性肺炎(HAP)的临床疗效、细菌学疗效、安全性与经济学效果。方法选取HAP患者120例,随机分为两组,每组各60例,分别使用特治星(4.0g哌拉西林+0.5g他唑巴坦,8∶1的配比)和佐朋(1.0g哌拉西林+0.25g他唑巴坦,4∶1的配比)治疗,连续治疗两周;治疗后比较两组的临床疗效、细菌学疗效、安全性与经济学效果。结果特治星组与佐朋组临床有效率分别为81.7%、80.0%,细菌清除率分别为78.3%、75.0%,差异均无统计学意义;特治星组与佐朋组的不良反应发生率分别为11.7%、3.3%,日均治疗费用分别为(360.5±60.8)元、(192.0±42.5)元,差异均有统计学意义(P<0.05)。结论佐朋与特治星治疗医院获得性肺炎疗效相当,但佐朋的剂量更小、不良反应发生率更低、安全性更高,日均治疗费用更低、更符合用药经济学原理。 OBJECTIVE To explore the clinical efficacy,bacteriological efficacy,safety,and economic effect of treating hospital acquired pneumonia(HAP) with different proportions of piperacillin/tazobactam.METHODS A total of 120 patients with HAP were selected and divided into 2 groups randomly,60 cases in each group,retrospectively treated by tazocin(4.0g piperacillin plus 0.5g tazobactam,in 8∶1 ratio) and Zuo Peng(1.0g piperacillin plus 0.25g tazobactam,in 4∶1 ratio) for 2 weeks;the clinical and bacteriological efficacy,safety and economic effect of the 2 groups were compared after treatment.RESULTS The effective rates of Tazocin group and Zuo Peng group were 81.7% and 80.0% respectively,and the bacterial clearance rates were 78.3% and 75.0%,there were no significant differences;the incidence rates of adverse reactions of Tazocin group and Zuo Peng group were 11.7% and 3.3%,and average costs for daily treatment were(360.5± 60.8) yuan and(192.0± 42.5)yuan,there were significant differences(P0.05 or P0.01).CONCLUSION The effect of Zuo Peng equals to Tarocin on the treatment of HAP,with the dose smaller,the incidence of adverse reaction lower,the safety higher,and with less costs for daily treatment,which is more in line with the principles of pharmacy economics.
出处 《中华医院感染学杂志》 CAS CSCD 北大核心 2012年第9期1897-1899,共3页 Chinese Journal of Nosocomiology
关键词 医院获得性肺炎 哌拉西林/他唑巴坦 佐朋 特治星 Hospital acquired pneumonia Piperacillin/tazobactam Zuo Peng Tarocin
  • 相关文献

参考文献8

二级参考文献28

共引文献48

同被引文献48

  • 1刘如安.耐碳青霉烯类肺炎克雷伯菌下呼吸道感染患者临床特征及危险因素分析[J].中南医学科学杂志,2020,0(2):141-145. 被引量:19
  • 2Johnson CA,Kelloway JS,Tonelli A,et al.Single-does pharmackinetics of piperacillin and Tazobactam in patients with renal disease[J].Clin Pharmacol Ther,1992,51(1):32-36.
  • 3Frank U,Mutter J,Schmidt-Eisenlohr E,et al.Comparative in vitro activity of piperacillin-sulbactam and piperacillintazobactam against nosocomial pathogens isolated from intensive care patients[J].Clin Microbiol Infect,2003,9(11):1128-1132.
  • 4Arzuaga A.Quantitation and stability of piperacilin and tazobactam in plasma and ultrafiltrate from patient undergping continuous venovenous hemofiltration by HPLC biomed[J].Chromatogr,2005,19(8):570-580.
  • 5Ito I,Kadowaki S,Tanabe N,et al.Tazobactam/piperacillin for moderate-to-severe pneumonia in patients with risk for aspiration:Comparison with imipenem/cilastatin[J].Pulm Pharmacol Ther,2010,23(5):403-410.
  • 6Adam D,Linglof T,Floret D,et al.Piperacillin/tazobactam versus cefotaxime plus mktronidazole for the treatment of severe intra-abdominal infection in hospitalized pediatric patients[J].Curr Ther Res Clin Exp,2001,62(6):488-502.
  • 7Gesser RM,McCarroll KA,Woods GL.Efficacy of ertapenem against methicillin-susceptible Staphylococcus aureus in complicated skin/skin structure infections:results of a double-blind clinical trial versus piperacillintazobactam[J].Inter J Antimicrobial Agents,2004,23(7):235-239.
  • 8Falcone M,Russo A,Cangemi R,et al. Lower mortality rate in elderlypatients with community-onset pneumonia on treatment with aspirin[J]. J Am Heart Assoc,2015 ,4( 1 ) :e001595.
  • 9李维香.基层医院下呼吸道感染病原学及耐药分析.天津医科大学,2013.
  • 10彭凤英,贾蓓,唐君,刘成伟,黄文祥,张唯力,胡自立,颜春松,王金根,吕晓菊,江南.哌拉西林/三唑巴坦(4∶1)治疗急性细菌性感染多中心、随机、双盲对照临床研究[J].中国抗生素杂志,2008,33(2):114-120. 被引量:8

引证文献5

二级引证文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部